Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes
Efficacy of empagliflozin in patients with heart failure across kidney risk categories
Medical Disclaimer This article is for educational purposes only and should not replace individualized medical advice, diagnosis, or treatment
Different formulations within this class have dramatically different half-lives, ranging from hours to days, which directly impacts their dosing frequency and elimination timeline
We know this transition can feel daunting, but youre stronger than you realize, and were here to cheer you on with solutions that make a difference
Shi, I., et al., Semaglutide eligibility across all current indications for US adults, JAMA Cardiology , Nov